Jubilant Pharma Launches Hydroxychloroquine Sulfate Tablets

New Delhi: Jubilant Pharma Ltd. and Aavis Pharmaceuticals Inc. have recently announced the launch of Hydroxychloroquine Sulfate tablets, 200 mg, a therapeutic equivalent version of Plaquenil (hydroxychloroquine sulfate) 200 mg in the U.S. market. The product will be distributed by Jubilant Cadista, a unit of Jubilant Pharma Ltd.

Hydroxychloroquine Sulfate Tablets are indicated for the treatment of:

• Malaria
• Lupus Erythematosus
• Rheumatoid Arthritis

"We are pleased to announce the commercial launch of Hydroxychloroquine Sulfate tablets in the U.S. through our marketing partner," stated Ashok Barot, Chairman, Aavis Pharmaceuticals.

"Our team is doing their best to fulfil the current surge in demand. We'll continue our efforts to be a significant and reliable supplier of this product," stated Swapnil Shah, Managing Director, Senores Pharmaceuticals, R&D partner and an affiliate of Aavis Pharmaceuticals.

"We are excited about this launch," stated Pramod Yadav, CEO, Jubilant Pharma Limited. "We are pleased to partner with Aavis to create access for the growing demand for this product and expand our basket of offerings in the US market."

U.S. annual market size for Hydroxychloroquine Sulfate Tablets, 200 mg was approximately US$237 million (IQVIA MAT June 2020).

Read also: Saptagir Labs, Jubilant Generics join hands to manufacture Remdesivir

Jubilant Pharma Limited (JPL), a company incorporated under the laws of Singapore and a wholly owned subsidiary of Jubilant Life Sciences Limited, is an integrated global Pharmaceutical company engaged in manufacturing and supply of APIs, Solid Dosage Formulations, Radiopharmaceuticals, Allergy Therapy Products and Contract Manufacturing of Sterile Injectables and Non Sterile products through six USFDA approved manufacturing facilities in the US, Canada and India and a network of 49 radiopharmacies in the US.

Read also: Jubilant Life Sciences launches remdesivir under brand name JUBI-R in India